vs
Side-by-side financial comparison of FIRST HORIZON CORP (FHN) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
FIRST HORIZON CORP is the larger business by last-quarter revenue ($888.0M vs $619.8M, roughly 1.4× QuidelOrtho Corp). FIRST HORIZON CORP runs the higher net margin — 29.4% vs -14.8%, a 44.2% gap on every dollar of revenue. On growth, FIRST HORIZON CORP posted the faster year-over-year revenue change (21.8% vs -10.5%). Over the past eight quarters, FIRST HORIZON CORP's revenue compounded faster (20.0% CAGR vs -6.6%).
First Horizon Corporation, formerly First Tennessee Bank, is a financial services company, founded in 1864, and based in Memphis, Tennessee. Through its banking subsidiary First Horizon Bank, it provides financial services through locations in 12 states across the Southeast, a region in which it is the fourth largest regional bank.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
FHN vs QDEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $888.0M | $619.8M |
| Net Profit | $261.0M | $-91.8M |
| Gross Margin | — | — |
| Operating Margin | 38.5% | — |
| Net Margin | 29.4% | -14.8% |
| Revenue YoY | 21.8% | -10.5% |
| Net Profit YoY | 57.2% | — |
| EPS (diluted) | $0.51 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $619.8M | ||
| Q4 25 | $888.0M | — | ||
| Q3 25 | $889.0M | $699.9M | ||
| Q2 25 | $830.0M | $613.9M | ||
| Q1 25 | $812.0M | $692.8M | ||
| Q4 24 | $729.0M | $707.8M | ||
| Q3 24 | $827.0M | $727.1M | ||
| Q2 24 | — | $637.0M |
| Q1 26 | — | $-91.8M | ||
| Q4 25 | $261.0M | — | ||
| Q3 25 | $262.0M | $-733.0M | ||
| Q2 25 | $241.0M | $-255.4M | ||
| Q1 25 | $218.0M | $-12.7M | ||
| Q4 24 | $166.0M | $-178.4M | ||
| Q3 24 | $218.0M | $-19.9M | ||
| Q2 24 | — | $-147.7M |
| Q1 26 | — | — | ||
| Q4 25 | 38.5% | — | ||
| Q3 25 | 38.7% | -100.7% | ||
| Q2 25 | 37.2% | -29.4% | ||
| Q1 25 | 35.1% | 4.7% | ||
| Q4 24 | 28.8% | -14.2% | ||
| Q3 24 | 34.0% | 2.1% | ||
| Q2 24 | — | -18.4% |
| Q1 26 | — | -14.8% | ||
| Q4 25 | 29.4% | — | ||
| Q3 25 | 29.5% | -104.7% | ||
| Q2 25 | 29.0% | -41.6% | ||
| Q1 25 | 26.8% | -1.8% | ||
| Q4 24 | 22.8% | -25.2% | ||
| Q3 24 | 26.4% | -2.7% | ||
| Q2 24 | — | -23.2% |
| Q1 26 | — | $-1.35 | ||
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.50 | $-10.78 | ||
| Q2 25 | $0.45 | $-3.77 | ||
| Q1 25 | $0.41 | $-0.19 | ||
| Q4 24 | $0.29 | $-2.54 | ||
| Q3 24 | $0.40 | $-0.30 | ||
| Q2 24 | — | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $140.4M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $8.8B | $1.9B |
| Total Assets | $83.9B | $5.6B |
| Debt / EquityLower = less leverage | — | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $140.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $98.3M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | — | $107.0M |
| Q1 26 | — | $2.5B | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $8.8B | — | ||
| Q3 25 | $8.9B | $2.0B | ||
| Q2 25 | $9.0B | $2.8B | ||
| Q1 25 | $8.7B | $3.0B | ||
| Q4 24 | $8.8B | $3.0B | ||
| Q3 24 | $9.0B | $3.2B | ||
| Q2 24 | — | $3.2B |
| Q1 26 | — | $5.6B | ||
| Q4 25 | $83.9B | — | ||
| Q3 25 | $83.2B | $5.7B | ||
| Q2 25 | $82.1B | $6.4B | ||
| Q1 25 | $81.5B | $6.5B | ||
| Q4 24 | $82.2B | $6.4B | ||
| Q3 24 | $82.6B | $6.8B | ||
| Q2 24 | — | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $396.0M | — |
| Free Cash FlowOCF − Capex | $389.0M | — |
| FCF MarginFCF / Revenue | 43.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 1.52× | — |
| TTM Free Cash FlowTrailing 4 quarters | $595.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $396.0M | — | ||
| Q3 25 | $-200.0M | $-45.5M | ||
| Q2 25 | $83.0M | $-46.8M | ||
| Q1 25 | $349.0M | $65.6M | ||
| Q4 24 | $191.0M | $63.7M | ||
| Q3 24 | $389.0M | $117.9M | ||
| Q2 24 | — | $-97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $389.0M | — | ||
| Q3 25 | $-208.0M | $-94.7M | ||
| Q2 25 | $74.0M | $-84.3M | ||
| Q1 25 | $340.0M | $9.4M | ||
| Q4 24 | $174.0M | $16.5M | ||
| Q3 24 | $383.0M | $71.4M | ||
| Q2 24 | — | $-133.2M |
| Q1 26 | — | — | ||
| Q4 25 | 43.8% | — | ||
| Q3 25 | -23.4% | -13.5% | ||
| Q2 25 | 8.9% | -13.7% | ||
| Q1 25 | 41.9% | 1.4% | ||
| Q4 24 | 23.9% | 2.3% | ||
| Q3 24 | 46.3% | 9.8% | ||
| Q2 24 | — | -20.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | — | ||
| Q3 25 | 0.9% | 7.0% | ||
| Q2 25 | 1.1% | 6.1% | ||
| Q1 25 | 1.1% | 8.1% | ||
| Q4 24 | 2.3% | 6.7% | ||
| Q3 24 | 0.7% | 6.4% | ||
| Q2 24 | — | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | 1.52× | — | ||
| Q3 25 | -0.76× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 1.60× | — | ||
| Q4 24 | 1.15× | — | ||
| Q3 24 | 1.78× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FHN
| Commercial Consumer And Wealth Segment | $776.0M | 87% |
| Other | $88.0M | 10% |
| Corporate | $24.0M | 3% |
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
